中文摘要：

目的对比雷珠单抗与康柏西普治疗湿性老年性黄斑变性的临床疗效。方法湿性老年性黄斑变性患者40例（40眼）,分为雷珠单抗组与康柏西普组各20例,分别给予玻璃体腔注射雷珠单抗0.1 ml、康柏西普0.1 ml。注射前及注射1周、1个月及3个月后检测两组患者裸眼视力,光学相关断层扫描仪检测黄斑中心凹视网膜厚度,注射1个月、3个月后眼底荧光造影检测脉络膜新生血管形成（CNV）渗漏。结果治疗后各时间点雷珠单抗组的视力均高于康柏西普组,黄斑中心凹视网膜厚度薄于康柏西普组（P〈0.05）,但视力及黄斑中心凹视网膜厚度的时间与分组无交互效应（P〉0.05）。注射1个月、3个月后,两组CNV渗漏治疗均有效,两组有效率比较差异无统计学意义（P〉0.05）。结论与雷珠单抗相比,康柏西普玻璃体腔注射减轻湿性老年性黄斑变性患者的CNV渗漏的效果相当,而对视力及黄斑中心凹视网膜厚度的改善稍差,但是随着时间的延长,应可以达到相同的疗效。

英文摘要：

Objective To compare the clinical efficacy of ranibizumab with conbercept for wet age-related macular degeneration.Methods Forty patients（ 40 eyes） diagnosed as wet age-related macular degeneration were divided into ranibizumab group and conbercept group,with 20 cases in each group. Intravitreal injection with ranibizumab（ 0. 1 ml） and conbercept（ 0. 1 ml） was conducted in the ranibizumab group and conbercept group respectively. Before injection,after 1 week,1,3 and 6 months of injection,the uncorrected visual acuity was assessed and the thickness of macular fovea was detected by optical coherence tomography in both groups. After 1 and 3 months of injection,the leakage of choroidal neovascularization（ CNV） was detected by fundus fluorescein angiography. Results The ranibizumab group obtained higher uncorrected visual acuity and thinner thickness of macular fovea compared to the conbercept group at each time point after treatment（ P〈0. 05）,but there was no interaction effect in the uncorrected visual acuity or the thickness of macular fovea（ P〉0. 05）. After 1 and 3 months of injection,the treatment for the leakage of CNV was effective in both group,and there was no statistical difference in the effective rate between two groups（ P〈0. 05）.Conclusion Compared to ranibizumab,intravitreal injection with conbercept also can alleviate the leakage of CNV in patients with wet age-related macular degeneration,and has poorer efficacy on the improvement of uncorrected visual acuity and thickness of macular fovea,but might obtain the same efficacy with the increase of time.